Hepatitis C News and Research

Latest Hepatitis C News and Research

Sexual impairment common among men undergoing chronic hepatitis C treatment

Sexual impairment is common among men with chronic hepatitis C undergoing antiviral therapy, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

1 Sep 2009

Cancer researcher to serve as Peregrine Pharmaceuticals' clinical advisor for bavituximab cancer program

Peregrine Pharmaceuticals, Inc., today announced that noted cancer researcher Bruce Chabner, M.D., will serve as a clinical advisor to the company on the design of clinical trials for the bavituximab cancer program.

31 Aug 2009

Caucasians have a higher rate of HBV recurrence compared to Asian Americans and African Americans

According to the Centers for Disease Control and Prevention (CDC) 1.5 to 2 million Americans are infected with the hepatitis B virus (HBV). Prior studies have shown there to be significant racial differences in access to and outcomes of liver transplantation. Recently, doctors from across the U.S. conducted a multicenter retrospective-prospective study of the waitlist status and outcomes of liver transplant patients with HBV infection.

28 Aug 2009

Lakewood-Amedex to speed up development of its broad spectrum anti-influenza product into clinical studies

Lakewood-Amedex Inc., (L-A), the anti-infectives biopharmaceutical company developing a unique portfolio of anti-bacterial and anti-viral products including NuBiotics, a novel family of synthetic anti-bacterial compounds, and anti-viral products against hepatitis, HIV and influenza, announced today that it is accelerating development of its broad spectrum anti-influenza product into clinical studies.

27 Aug 2009

Novelos Therapeutics enters into a definitive agreement with Purdue Pharma to raise funds

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos entered into a definitive agreement with Purdue Pharma L.P., an existing investor, to sell 13,636,364 shares of its common stock and warrants, expiring on December 31, 2015, to purchase an aggregate of approximately 4,772,728 shares of common stock at an exercise price of $0.66 per share, for gross proceeds of $9 million.

27 Aug 2009

Relationship between the CD14 variation and the formation of portal lymphoid aggregates discovered

It is still unknown why the natural history of chronic disease caused by hepatitis C virus (HCV), which currently infects 3% of the world's population, varies from mild in some patients to rapidly progressing in others. Age, sex, alcohol consumption and liver sensitivity to gut-derived bacterial endotoxins, were the early factors defined to enhance the risk of fibrosis progression.

27 Aug 2009

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research expanding its studies of anti-phosphatidylserine (anti-PS) antibodies as potential treatments for viral hemorrhagic fever (VHF) infections.

26 Aug 2009

Profectus BioSciences to conduct proof-of-concept studies with its rVSV vector technology

Profectus BioSciences, Inc. (Profectus), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates for serious chronic infections, announced today it has entered into a research collaboration agreement with the PATH Malaria Vaccine Initiative (MVI) to conduct proof-of-concept studies with its proprietary, recombinant vesicular stomatitis virus (rVSV) vector technology as a preventative malaria vaccine.

26 Aug 2009

Study suggests that connective tissue growth factor plays a vital role in liver fibrosis progression

Accumulating evidence suggests that connective tissue growth factor (CCN2) plays a central role in fibrotic conditions in many organ systems. Fibrosis is a scarring condition that is characterized by excessive collagen production that impedes normal cell function and can cause organ dysfunction and failure.

25 Aug 2009

Tripep and Cosmix AG license RAS and mRNA Display Library technologies

Tripep and the German biotech company Cosmix AG have both licensed their respective technologies (RAS and mRNA Display Library) to a newly formed US company named Opsonic Therapeuticals Inc. within which Tripep’s RAS technology will be developed.

25 Aug 2009

FDA accepts for filing Salix Pharmaceuticals' NDA for rifaximin tablets

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the Food and Drug Administration (FDA) has accepted for filing and designated for Priority Review the Company’s New Drug Application (NDA) for rifaximin tablets 550 mg for the maintenance of remission of hepatic encephalopathy (HE). Additionally, the FDA has informed the Company of its plan to schedule an Advisory Committee meeting in late February 2010 to discuss the application.

25 Aug 2009

Study reveals safety of ConvaTec's advanced antimicrobial dressing

ConvaTec, a world-leading provider of innovative medical technologies for community and hospital care, today announced new data showing that AQUACEL(R) Ag, the company's advanced antimicrobial dressing, is safe for use in an MRI environment.

25 Aug 2009

Diplomat Specialty Pharmacy and Ohio Caresource collaborate to develop Chronic Kidney Disease treatment

Diplomat Specialty Pharmacy announced today that its Diplomat Health Services Division is partnering with CareSource in Ohio to slow the progression of Chronic Kidney Disease (CKD), improve clinical outcomes and reduce healthcare costs associated with the disease. As the number of Americans with CKD continues to rise, CareSource is focused on the early identification and treatment of their patients with the illness.

25 Aug 2009

Researchers discover elusive nanoscale movements of ribosomes at work

Researchers at the University of California, Berkeley, have for the first time captured elusive nanoscale movements of ribosomes at work, shedding light on how these cellular factories take in genetic instructions and amino acids to churn out proteins.

24 Aug 2009

The California Chronic Care Coalition launches new website to share information on chronic conditions

The California Chronic Care Coalition (CCCC) continues to advance its work toward meaningful and responsible health care reform with the launching of its consumer website: www.chroniccareca.org. Designed to help build a healthier California, the website is aimed at the more than 16 million Californians with chronic conditions such as Asthma, Diabetes, Alzheimer’s Heart disease, Epilepsy and Multiple Sclerosis.

24 Aug 2009

Safe injection practices for improving safety to be discussed at the Joint Commission Infection Control Conference

Premier healthcare alliance’s Gina Pugliese, vice president of Premier’s Safety Institute, will share insights on safe injection practices to improve patient and worker safety at the Joint Commission Infection Control Conference on August 21 in Crystal City, Va.

21 Aug 2009

Genetic engineering technique used to treat bowel disorders

For the first time, scientists have used a genetically engineered "friendly" bacterium to deliver a therapy.

21 Aug 2009

Seasonal flu vaccinations to cost less in Safeway's U.S. Stores

Safeway Inc. (NYSE:SWY) added to its leadership reputation in health care reform and cost control by offering seasonal flu vaccines in its U.S. stores at a substantial savings compared with the cost of doctor-administered vaccines. The lower cost will help consumers and businesses control health care spending in a challenging economy.

20 Aug 2009

USPTO grants MultiCell Technologies patent for its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines

MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) announced today it has been granted U.S. patent 7,566,567 by the United States of America Patent and Trademark Office covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines.

20 Aug 2009

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Inovio Biomedical Corporation (NYSE AMEX: INO) (“Inovio”) today reported financial results for the three and six months ended June 30, 2009. Total revenue of $2.5 million and $2.9 million for the three and six months ended June 30, 2009, compared to $663,000 and $1.3 million for the three and six months ended June 30, 2008, respectively.

20 Aug 2009

Hepatitis C News and Research

Latest Hepatitis C News and Research

Sexual impairment common among men undergoing chronic hepatitis C treatment

Cancer researcher to serve as Peregrine Pharmaceuticals' clinical advisor for bavituximab cancer program

Caucasians have a higher rate of HBV recurrence compared to Asian Americans and African Americans

Lakewood-Amedex to speed up development of its broad spectrum anti-influenza product into clinical studies

Novelos Therapeutics enters into a definitive agreement with Purdue Pharma to raise funds

Relationship between the CD14 variation and the formation of portal lymphoid aggregates discovered

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

Profectus BioSciences to conduct proof-of-concept studies with its rVSV vector technology

Study suggests that connective tissue growth factor plays a vital role in liver fibrosis progression

Tripep and Cosmix AG license RAS and mRNA Display Library technologies

FDA accepts for filing Salix Pharmaceuticals' NDA for rifaximin tablets

Study reveals safety of ConvaTec's advanced antimicrobial dressing

Diplomat Specialty Pharmacy and Ohio Caresource collaborate to develop Chronic Kidney Disease treatment

Researchers discover elusive nanoscale movements of ribosomes at work

The California Chronic Care Coalition launches new website to share information on chronic conditions

Safe injection practices for improving safety to be discussed at the Joint Commission Infection Control Conference

Genetic engineering technique used to treat bowel disorders

Seasonal flu vaccinations to cost less in Safeway's U.S. Stores

USPTO grants MultiCell Technologies patent for its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hepatitis C News and Research

Latest Hepatitis C News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in